ICH Q14: Pharma groups want clarity on benefits of enhanced approach
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesNorth AmericaPharmaceuticalsProduct LifecycleRegulatory NewsJoanne S. EglovitchBiologics/ biosimilars/ vaccinesNorth AmericaPharmaceuticalsProduct Lifecycle